期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
间变脑胶质瘤中异柠檬酸脱氢酶突变对患者术后替莫唑胺化学治疗及预后的影响:285例单中心回顾性研究 被引量:1
1
作者 杨沛 王宽宇 +3 位作者 张传宝 王政 游赣 单侠 《神经疾病与精神卫生》 2021年第5期323-331,共9页
目的分析间变脑胶质瘤中异柠檬酸脱氢酶(IDH)突变与患者临床病理学因素的相关性及对术后化学治疗敏感性的影响。方法回顾性连续纳入中国胶质瘤基因图谱计划(CGGA)数据库中接受开颅手术且术后病理诊断为间变脑胶质瘤(世界卫生组织Ⅲ级)患... 目的分析间变脑胶质瘤中异柠檬酸脱氢酶(IDH)突变与患者临床病理学因素的相关性及对术后化学治疗敏感性的影响。方法回顾性连续纳入中国胶质瘤基因图谱计划(CGGA)数据库中接受开颅手术且术后病理诊断为间变脑胶质瘤(世界卫生组织Ⅲ级)患者,术后接受放射治疗和(或)替莫唑胺(TMZ)化学治疗。肿瘤组织标本在放射治疗和(或)化学治疗前通过手术切除获得,使用QIAamp DNA Mini试剂盒按照说明书从冷冻肿瘤组织中提取基因组DNA,使用纳米滴ND-1000分光光度计测定DNA浓度和质量,进行IDH1/2突变、1p/19q缺失、MGMT启动子甲基化的检测。应用SPSS 16.0软件通过单因素和多因素Cox生存分析分析临床及分子病理因素与患者总生存期的相关性及对术后放射治疗和替莫唑胺化学治疗敏感性的影响;使用GraphpadPrism 8软件进行Kaplan-Meier曲线生存分析。结果共纳入285例间变脑胶质瘤患者,其中201例(70.5%)表现为IDH突变,84例(29.5%)表现为IDH野生。多因素Cox回归分析显示,IDH突变(HR=0.531,95%CI:0.385~0.733,P<0.001)及1p/19q联合缺失(HR=0.352,95%CI:0.179~0.691,P=0.002)均可独立预测患者总生存期,而O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化的预测价值差异无统计学意义(P=0.071)。IDH突变组中,接受术后TMZ化学治疗的患者较未接受者预后有所改善,但差异无统计学意义(中位生存期:1793 d比1455 d,P=0.059),而在IDH野生组中,TMZ化学治疗对患者预后改善不明显(中位生存期:535 d比415 d,P=0.890)。结论本研究发现IDH突变型间变脑胶质瘤在接受术后TMZ化疗后,预后有改善趋势,相关结果可能为今后WHOⅢ级脑胶质瘤术后化疗的研究提供思路。 展开更多
关键词 间变脑胶质瘤 异柠檬酸脱氢酶 突变 替莫唑胺 化学治疗 生存预后
原文传递
Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma 被引量:13
2
作者 JIN Qiang ZHANG Wei +5 位作者 QIU Xiao-guang YAN Wei you gan LIU Yan-wei JIANG Tao WANG Lei 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第17期2584-2588,共5页
Background Everlasting cellular proliferation is the fundamental feature during gliomagenesis and Ki-67 is one of the classical proliferation markers in human glioblastoma multiforme (GBM). However, the driver genes... Background Everlasting cellular proliferation is the fundamental feature during gliomagenesis and Ki-67 is one of the classical proliferation markers in human glioblastoma multiforme (GBM). However, the driver genes or core pathways for cellular proliferation in GBM have not been elucidated systematically. Methods We evaluated by immunohistochemistry the prognostic value of Ki-67 expression in the clinical outcome of 156 Chinese patients with GBM and a total of 64 GBM samples were selected for further Agilent genome-wide microarray analysis. On the basis of the microarray data from Tiantan (n--64) and The Cancer Genome Atlas (TCGA) (n=202) database, differentially expressed genes between the GBM subgroups with high or low level of Ki-67 expression were identified using Significance Analysis of Microarrays (SAM). Gene Ontology (GO) and KEGG Pathway analyses were then undertaken for the Ki-67 associated genes to identify the most significant biological processes and signaling pathways. Results We confirmed that Ki-67 was an independent prognostic indicator in the largest Chinese patient cohort of 156 GBM samples via immunohistochemical staining. Survival analysis of Ki-67 over-expression revealed a highly significant association with a worse clinical outcome (P=0.010 for progression-free survival; P=0.007 for overall survival). Comparative and integrated analysis between -Iqantan and TCGA database identified a 247-gene "proliferation signature" (205 up-regulated and 42 down-regulated genes) that distinguished Ki-67 expression phenotypes. GO and KEGG Pathway analyses further indicated that Ki-67 expression phenotype was associated with distinct changes in gene expression associated with the regulation of cellular growth and proliferation. Conclusions Proliferation marker Ki-67 is an independent prognostic indicator in Chinese GBM patients. And Ki-67 associated proliferation signature identified through genome-wide microarray analysis may provide potential targets for anti-proliferation therapy in GBM. 展开更多
关键词 GLIOBLASTOMA KI-67 cellular proliferation MICROARRAY IMMUNOHISTOCHEMISTRY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部